The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 11, 2023

Filed:

Sep. 19, 2018
Applicants:

Shi-lung Lin, Arcadia, CA (US);

Samantha Chang-lin, Arcadia, CA (US);

Donald Chang, Cerritos, CA (US);

Inventors:

Shi-Lung Lin, Arcadia, CA (US);

Samantha Chang-Lin, Arcadia, CA (US);

Donald Chang, Cerritos, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12N 15/11 (2006.01); C12P 19/34 (2006.01); C12N 15/70 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1135 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/70 (2013.01); C12P 19/34 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01); C12N 2330/50 (2013.01); C12N 2330/51 (2013.01);
Abstract

This invention generally relates to a composition and its method of use for inducing adult stem cell (ASC) expansion and/or derivation in vitro, using miR-302-like pre-miRNAs, shRNAs and/or siRNAs, all of which contain a shared sequence of 5'-UAAGUGCUUC CAUGUUU-3′ (SEQ ID NO: 7) in the 5′-end, and further in conjunction with the use of some wound-healing-related defined factors, including but not limited to basic fibroblast growth factor (bFGF)/fibroblast growth factor 2 (FGF-2), leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), Epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), tumor necrosis factor (TNF), stem cell factor (SCF), homeobox proteins (HOX), Notch, GSK, Wnt/beta-Catenin signals, interleukins, and/or bone morphogenetic proteins (BMPs). The principle of the present invention is related to a novel mechanism of inducible symmetric ASC division recently found in a skin wound healing model in vivo. The resulting amplified ASCs are useful for treating a variety of human aging- and cell dysfunction-associated disorders, including but not limited to Alzheimer's disease, Parkinson's disease, motor neuron disease, stroke, diabetes, osteoporosis, myocardial infraction, hemophilia, anemia, AIDS, leukemia, lymphoma and many kinds of cancers as well as aging.


Find Patent Forward Citations

Loading…